Tollys appoints Philippe Goupit as chairman of the board
With more than 35 years experience in the pharmaceutical industry and biotech, Philippe Goupit will lead Tollys’ plans for growth.
Tollys extends its executive management team with appointment of Bettina Werle as CSO
Bettina Werle will supervise the laboratory, help set its scientific priorities and lead Tollys’ R&D team.
Tollys receives over €1.5 million deep tech financing from Bpifrance
Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Tollys closes pre-Series A financing of €2.3 million
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
Release of c-FLIP brake selectively sensitizes human cancer cells to TLR3-mediated apoptosis.
Alkurdi L, Virard F, Vanbervliet B, Weber K, Toscano F, Bonnin M, Le Stang N, Lantuejoul S, Micheau O, Renno T, Lebecque S, Estornes Y.
Cell Death Dis. 2018 Aug 29; 9(9):874
Recent Comments